Measurement challenges in immuno-oncology and novel therapies: Harmonising Toxicity and Response Assessment Across Immune Checkpoint Inhibitors, CAR-T, bispecific antibodies, and radioligand therapies
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Measurement challenges in immuno-oncology and novel therapies: Harmonising Toxicity and Response Assessment Across Immune Checkpoint Inhibitors, CAR-T, bispecific antibodies, and radioligand therapies. // Measurement and Evaluations in Cancer Care . – URL: https://www.sciencedirect.com/science/article/pii/S2949877526000122?dgcid=rss_sd_all
Measurement challenges in immuno-oncology and novel therapies: Harmonising Toxicity and Response Assessment Across Immune Checkpoint Inhibitors, CAR-T, bispecific antibodies, and radioligand therapies. Measurement and Evaluations in Cancer Care . https://www.sciencedirect.com/science/article/pii/S2949877526000122?dgcid=rss_sd_all
“Measurement challenges in immuno-oncology and novel therapies: Harmonising Toxicity and Response Assessment Across Immune Checkpoint Inhibitors, CAR-T, bispecific antibodies, and radioligand therapies.” Measurement and Evaluations in Cancer Care .
@article{article57771,
title = {Measurement challenges in immuno-oncology and novel therapies: Harmonising Toxicity and Response Assessment Across Immune Checkpoint Inhibitors, CAR-T, bispecific antibodies, and radioligand therapies},
journal = {Measurement and Evaluations in Cancer Care },
url = {https://www.sciencedirect.com/science/article/pii/S2949877526000122?dgcid=rss_sd_all}
}